IPCA Laboratories (IPCALAB.NS) Stock Price

IPCA Laboratories Price

NSE·CLOSED
1,867.40
​
Market closed

Revenue has compounded at 13.1% per year over the past 19 years to 95.63 B INR. Earnings per share have grown at 12.2% per year over the last 19 years. IPCA Laboratories's net margin stands at 11.9%, down from 15.2% several years earlier. IPCA Laboratories currently offers a dividend yield of about 0.11%. The payout ratio is around 12% of earnings. The dividend has grown at 5.3% per year over the past 19 years. Analysts set a median price target of 1,632.00 INR, implying 12.6% below the current price. Of 20 analysts, 16 rate the stock a buy — an overall Buy consensus.

IPCA Laboratories stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IPCA Laboratories business model & stock analysis

Ipca Laboratories Ltd. generates revenue through the manufacturing and marketing of over 350 pharmaceutical formulations and approximately 80 active pharmaceutical ingredients (APIs), including Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts, and Propranolol. The company sells its branded products such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, and Venpower in more than 100 countries globally. Its subsidiaries, Ipca Pharmaceuticals, Inc., Ipca Laboratories (U.K.) Ltd, and Tonira Exports Limited, support the distribution and sales of these products across international markets. The company's primary customers are healthcare providers, hospitals, and pharmacies in over 100 countries, purchasing both generic APIs and branded formulations. Manufacturing units in India produce APIs and formulations, with the firm's subsidiaries facilitating global market access. The therapeutic segments covered by its products include cardiovascular, antimalarial, and gastrointestinal treatments, among others, driven by the demand for cost-effective pharmaceutical solutions.

Frequently asked questions about IPCA Laboratories

Analysts currently set an average price target of 1,612.89 INR for the IPCA Laboratories stock (median: 1,632.00 INR), implying -13.0 % versus the latest price. The consensus is based on 20 analyst ratings.

20 analysts currently rate the IPCA Laboratories stock: 16 recommend buying, 3 holding and 1 selling.

Converted at the current exchange rate, the IPCA Laboratories share trades at 18.22 EUR (1,867.40 INR).

The IPCA Laboratories share (IPCALAB.NS) is listed on 2 stock exchanges, including: NSE (Indien) (IPCALAB.NS).

The revenue of IPCA Laboratories is 95.63 B INR. This figure is based on current financial data and reflects the company's business performance.

The profit of IPCA Laboratories is 11.41 B INR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of IPCA Laboratories is currently 41.52. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the IPCA Laboratories stock.

The price-to-sales ratio (P/S) of IPCA Laboratories is currently 4.95. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the IPCA Laboratories stock.

The Eulerpool Quality Score for IPCA Laboratories is 9/10.

The ISIN of IPCA Laboratories is INE571A01038. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of IPCA Laboratories is IPCALAB.NS. The ticker symbol is used to trade IPCA Laboratories shares on the stock exchange.

Fair ValueTerminal
1,699.33 INR
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
5.91 M INR
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website ipca.com
Country
Currency
INR
Initial public offering
Feb 23, 1994
ISIN
INE571A01038
Cusip
Y4175R161
Market capitalization
473.76 B INRMega Cap
52-Week Range
PEG
3.70
P/E ratio
P/Ee 2027
31.28
P/Ee 2028
26.42
P/Ee 2029
22.74
P/S
P/Se
4.26
EV/EBIT
28.86
P/B Ratio
5.88
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
13.96 %
Dividend
Dividend yield
0.11 %
Est. Dividend Yield
0.64 %
Payout Ratio
12.06 %
Dividend growth Ø5Y
-21.00 %
Dividend payments per year
1
Dividend paid since
9 years
Dividend not reduced since
0 years
Dividend increased since
0 years
Dividend withholding tax
20.00 %
Last updated Nov 19, 2026, 9:47 PM

IPCA Laboratories Peer Group

IPCA Laboratories Ticker

BSE · IPCALAB.BONSE INDIA · IPCALAB.NS

IPCA Laboratories FIGI

IPCA:IN · BBG000D4LPY0IPCA:IB · BBG000D4LQN0IPCA:IS · BBG000D4LR21IPCA:IG · BBG003NVYQ40